scholarly journals 3D Printed Skin-Wash Sampler for Sweat Sampling in Cystic Fibrosis Diagnosis Using Capillary Electrophoretic Ion Ratio Analysis

Separations ◽  
2021 ◽  
Vol 8 (12) ◽  
pp. 234
Author(s):  
Miriam Malá ◽  
Petra Itterheimová ◽  
Lukáš Homola ◽  
Jana Vinohradská ◽  
Petr Kubáň
Keyword(s):  
Cystic Fibrosis ◽  
Skin Surface ◽  
Single Step ◽  
Ratio Analysis ◽  
Sweating Rate ◽  
Sampling Device ◽  
Sweat Chloride ◽  
3D Printed ◽  
Flow Through ◽  
Capillary Electrophoretic

Sweat chloride analysis is one of the important approaches in cystic fibrosis diagnosis. The commonly used Macroduct method to acquire sweat samples is semi-invasive, time consuming and expensive. Furthermore, this method often fails to collect a sufficient amount of sweat in newborns due to the insufficient sweating rate. In this work, we present a novel, simple, 3D-printed sampling device that is used to collect sweat specimens completely noninvasively in less than one minute. The device has a flow-through channel adjacent to the skin surface, through which 500 µL of deionized water is flushed and the spontaneously formed sweat on the skin in the channel area is washed into a plastic vial. The developed skin-wash procedure is a single step operation, is completely noninvasive and it always produces a sweat specimen. The ions from the skin-wash are subsequently analyzed by capillary electrophoresis with contactless conductivity detection and selected ion ratio (Cl−/K+) or ((Cl− + Na+)/K+) is used as a cut-off value to diagnose cystic fibrosis patients with sensitivity and specificity comparable to the conventional Macroduct method.

scholarly journals Development of a portable 3D-printed flow-through passive sampling device free of flow pattern effects

2018 ◽  
Vol 143 ◽  
pp. 359-366 ◽  
Author(s):  
Fidelis Nitti ◽  
M. Inês G.S. Almeida ◽  
Richard Morrison ◽  
Robert W. Cattrall ◽  
Vincent J. Pettigrove ◽  
...  
Keyword(s):  
Flow Pattern ◽  
Passive Sampling ◽  
Sampling Device ◽  
3D Printed ◽  
Flow Through ◽  
Device Free ◽  
Passive Sampling Device

3D printed object’s strength-to-weight ratio analysis for M3 liquid material

2020 ◽  
pp. 1-15
Author(s):  
Mohammadreza Lalegani Dezaki ◽  
Mohd Khairol Anuar Mohd Ariffin ◽  
Diniesh Appalanaidoo ◽  
Zaliha Wahid ◽  
Abdullahi Musse Rage
Keyword(s):  
Weight Ratio ◽  
Ratio Analysis ◽  
Liquid Material ◽  
3D Printed

Micro-flowcell conductometric sweat analysis for cystic fibrosis diagnosis

2000 ◽  
Vol 37 (3) ◽  
pp. 399-407 ◽  
Author(s):  
H Lewis Webster ◽  
Carmelo G Quirante
Keyword(s):  
Power Supply ◽  
Time Interval ◽  
Sweating Rate ◽  
Sensor Cell ◽  
Sweat Testing ◽  
Small Holders ◽  
Flow Through ◽  
To Receive ◽  
Conductivity Cell ◽  
Sweat Tests

This paper describes a device specifically designed to facilitate neonatal sweat testing. The components are sized appropriately for attachment to the limbs of newborns. Iontophoretic electrodes, with pilocarpine gel inserts, are latched into small holders attached by straps to the limb. The holder at the anodic site remains in place to receive and align the sensor cell, which uses a conical collecting surface to channel the sweat directly and anaerobically from the sweat ducts to the continuous flow-through conductivity cell within its body. A crib-side analysis unit incorporates an iontophoretic power supply and displays a continuous readout of sweat electrical conductivity. The average conductivity during a specific time interval and the initial sweating rate are automatically displayed. The method, which simplifies sweat tests, is currently being assessed in three neonatal clinical trials to test its ability to reduce test failures in the newborn due to insufficient sweat.

ΔF508 Genotype Does Not Predict Disease Severity in an Ethnically Diverse Cystic Fibrosis Population

PEDIATRICS ◽  
1994 ◽  
Vol 93 (1) ◽  
pp. 114-118
Author(s):  
Lucille A. Lester ◽  
Jerome Kraut ◽  
John Lloyd-Still ◽  
Theodore Karrison ◽  
Carol Mott ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Disease Severity ◽  
Ethnically Diverse ◽  
Clinical Parameter ◽  
Population Based ◽  
Age At Diagnosis ◽  
Chest Roentgenogram ◽  
Sweat Chloride ◽  
Cystic Fibrosis Population ◽  
Cftr Mutations

Objective. As part of a study to determine population-based frequencies of CFTR mutations in an ethnically diverse, midwestern cystic fibrosis (CF) population, clinical histories were studied in 119 CF patients. Methodology. We sought to examine the association between genotype as characterized by the ΔF508 and 11 other commonly occurring mutations and clinical parameters including age at diagnosis, clinical presentation, sweat chloride level, chest roentgenogram score, clinical scores, pulmonary function test results, percent weight for height, and presence of associated CF complications. Results. Age at diagnosis of CF was significantly associated with homozygosity for ΔF508 (mean age at diagnosis ± SE: 1.7 ± 0.3 years for ΔF508/ΔF508 vs 3.9 ± 0.9 years for ΔF508/other and other/other; P = .03). No other age-adjusted clinical parameter was significantly associated with ΔF508 or any other genotype. Conclusion. These data suggest that in this sample of CF patients, ΔF508 genotype is not predictive of disease severity. The lack of association between disease severity and genotype in this ethnically diverse sample may reflect the presence of more severe undetected mutations in our sample, or the effects of modifying genes at other, non-CF loci.

Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis

Thorax ◽  
2021 ◽  
pp. thoraxjnl-2020-216368
Author(s):  
Senne Cuyx ◽  
Anabela Santo Ramalho ◽  
Nikky Corthout ◽  
Steffen Fieuws ◽  
Eva Fürstová ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Image Analysis ◽  
Diagnostic Tool ◽  
Automated Image Analysis ◽  
Sweat Chloride ◽  
Morphology Analysis ◽  
Morphological Differences ◽  
Two Parameters ◽  
Analysis Protocol

Diagnosing cystic fibrosis (CF) when sweat chloride is not in the CF range and less than 2 disease-causing CFTR mutations are found requires physiological CFTR assays, which are not always feasible or available. We developed a new physiological CFTR assay based on the morphological differences between rectal organoids from subjects with and without CF. In organoids from 167 subjects with and 22 without CF, two parameters derived from a semi-automated image analysis protocol (rectal organoid morphology analysis, ROMA) fully discriminated CF subjects with two disease-causing mutations from non-CF subjects (p<0.001). ROMA, feasible at all ages, can be centralised to improve standardisation.

scholarly journals Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy

2020 ◽  
Vol 25 (3) ◽  
pp. 192-197 ◽  
Author(s):  
Kaden Ridley ◽  
Michelle Condren
Keyword(s):  
Cystic Fibrosis ◽  
Clinical Trials ◽  
Genetic Mutations ◽  
Transmembrane Conductance Regulator ◽  
Triple Combination ◽  
Transmembrane Conductance ◽  
Sweat Chloride ◽  
Cystic Fibrosis Transmembrane

Elexacaftor-tezacaftor-ivacaftor is a newly approved triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapy that contains 2 correctors and a potentiator of the CFTR channel. Its labeled indication for use is for persons 12 years of age and older with at least 1 F508del mutation for the CFTR gene. This drug combination provides potential therapy to many patients who had previously been excluded from CFTR modulation therapy due to the nature of their genetic mutations. The efficacy demonstrated in clinical trials surpasses the currently available therapies related to lung function, quality of life, sweat chloride reduction, and reducing exacerbations. The most common adverse events seen in clinical trials included rash and headache, and laboratory monitoring is recommended to evaluate liver function. Continued evaluation of patient data is needed to confirm its long-term safety and efficacy. Elexacaftor-tezacaftor-ivacaftor is a monumental and encouraging therapy for cystic fibrosis; however, approximately 10% of the CF population are not candidates for this or any other CFTR modulation therapy.

Sign in / Sign up

Export Citation Format

Share Document